FIXX insider filings
Q32 Bio Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-03-27. Screen FIXX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for FIXX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Q32 Bio Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-03-27 | 4 | Alloway Paul — See Remarks | Option exercise (M): 23,530 · Option exercise (M): 5,440 (derivative) @ $0 · Option exercise (M): 18,090 (derivative) @ $0 | EDGAR |
| 2024-03-27 | 4 | Michaud Charles Jr — See Remarks | Option exercise (M): 6,448 · Option exercise (M): 1,088 (derivative) @ $0 · Option exercise (M): 5,360 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | TZIANABOS ARTHUR — Director | Option exercise (M): 14,280 · Option exercise (M): 19,140 · Sale (S): 13,037 @ $0.57 · Option exercise (M): 14,280 (derivative) @ $0 · Option exercise (M): 19,140 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | Alloway Paul — See Remarks | Sale (S): 7,280 @ $0.57 | EDGAR |
| 2024-01-05 | 4 | Michaud Charles Jr — See Remarks | Sale (S): 1,708 @ $0.57 | EDGAR |
| 2024-01-03 | 4 | Michaud Charles Jr — See Remarks | Option exercise (M): 544 · Option exercise (M): 1,056 · Option exercise (M): 2,640 · Option exercise (M): 544 (derivative) @ $0 · Option exercise (M): 1,056 (derivative) @ $0 · Option exercise (M): 2,640 (derivative) @ $0 | EDGAR |
| 2024-01-03 | 4 | Alloway Paul — See Remarks | Option exercise (M): 4,420 · Option exercise (M): 5,280 · Option exercise (M): 8,910 · Option exercise (M): 4,420 (derivative) @ $0 · Option exercise (M): 5,280 (derivative) @ $0 · Option exercise (M): 8,910 (derivative) @ $0 | EDGAR |
| 2023-09-08 | 4 | Seymour Albert — See Remarks, Director | Option exercise (M): 4,620 · Sale (S): 1,448 @ $1.15 · Option exercise (M): 4,620 (derivative) @ $0 | EDGAR |
| 2023-08-07 | 4 | Jordan Julie — Chief Medical Officer | Option exercise (M): 1,548 @ $0 · Sale (S): 436 @ $1.39 · Option exercise (M): 387 @ $0 · Sale (S): 109 @ $1.39 · Option exercise (M): 4,644 @ $0 · Sale (S): 1,308 @ $1.39 · +3 more | EDGAR |
| 2023-08-04 | 4 | Jordan Julie — Chief Medical Officer | Option exercise (M): 350 @ $0 · Sale (S): 99 @ $1.31 · Option exercise (M): 350 (derivative) | EDGAR |
| 2023-06-15 | 4 | Poulton Jeffrey V. — Director | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | REICIN ALISE — Director | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | TZIANABOS ARTHUR — Director | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Patterson Matthew R — Director | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Thistle Mary — Director | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | GILLIS STEVEN — Director | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2023-03-06 | 4 | Alloway Paul — See Remarks | Sale (S): 10,965 @ $1.45 | EDGAR |
| 2023-02-27 | 4 | Alloway Paul — See Remarks | Grant/award (A): 164,000 (derivative) @ $0 · Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2023-02-27 | 4 | Blum Michael Lee — Chief Commercial Officer | Grant/award (A): 104,000 (derivative) @ $0 · Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-02-27 | 4 | Seymour Albert — See Remarks, Director | Grant/award (A): 632,000 (derivative) @ $0 · Grant/award (A): 105,000 (derivative) @ $0 | EDGAR |
| 2023-02-27 | 4 | Smith W Bradford — See remarks | Grant/award (A): 213,000 (derivative) @ $0 · Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2023-01-20 | 4/A | Blum Michael Lee — Chief Commercial Officer | Holdings only — no transactions reported | EDGAR |
| 2023-01-20 | 4/A | Alloway Paul — See Remarks | Holdings only — no transactions reported | EDGAR |
| 2023-01-20 | 4/A | Seymour Albert — See Remarks, Director | Holdings only — no transactions reported | EDGAR |
| 2023-01-11 | 4 | Blum Michael Lee — Chief Commercial Officer | Sale (S): 2,454 @ $1.39 | EDGAR |
| 2023-01-11 | 4 | Alloway Paul — See Remarks | Sale (S): 3,090 @ $1.39 | EDGAR |
| 2023-01-11 | 4 | Seymour Albert — See Remarks, Director | Sale (S): 3,620 @ $1.39 | EDGAR |
| 2023-01-11 | 4 | TZIANABOS ARTHUR — Director | Sale (S): 10,616 @ $1.39 | EDGAR |
| 2023-01-11 | 4 | Smith W Bradford — See Remarks | Sale (S): 3,729 @ $1.39 | EDGAR |
| 2023-01-04 | 4 | Blum Michael Lee — Chief Commercial Officer | Option exercise (M): 2,640 · Option exercise (M): 4,950 · Option exercise (M): 2,640 (derivative) @ $0 · Option exercise (M): 4,950 (derivative) @ $0 | EDGAR |
| 2023-01-04 | 4 | Seymour Albert — See Remarks, Director | Option exercise (M): 4,290 · Option exercise (M): 6,930 · Option exercise (M): 4,290 (derivative) @ $0 · Option exercise (M): 6,930 (derivative) @ $0 | EDGAR |
| 2023-01-04 | 4 | Alloway Paul — See Remarks | Option exercise (M): 4,290 · Option exercise (M): 5,280 · Option exercise (M): 4,290 (derivative) @ $0 · Option exercise (M): 5,280 (derivative) @ $0 | EDGAR |
| 2023-01-04 | 4 | TZIANABOS ARTHUR — Director | Option exercise (M): 13,860 · Option exercise (M): 19,140 · Option exercise (M): 13,860 (derivative) @ $0 · Option exercise (M): 19,140 (derivative) @ $0 | EDGAR |
| 2023-01-04 | 4 | Smith W Bradford — See Remarks | Option exercise (M): 6,600 · Option exercise (M): 6,930 · Option exercise (M): 6,600 (derivative) @ $0 · Option exercise (M): 6,930 (derivative) @ $0 | EDGAR |
| 2022-09-08 | 4 | Seymour Albert — See remarks, Director | Grant/award (A): 23,000 (derivative) @ $0 · Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Poulton Jeffrey V. — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | REICIN ALISE — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | PARMAR KUSH — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Gregory Richard J. — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Patterson Matthew R — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Thistle Mary — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | GILLIS STEVEN — Director | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-04-21 | 4 | Seymour Albert — See Remarks | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2022-02-28 | 4 | Kelly Timothy P — Chief Operating Officer | Grant/award (A): 28,200 (derivative) @ $0 · Grant/award (A): 4,800 (derivative) @ $0 | EDGAR |
| 2022-02-28 | 4 | Seymour Albert — Chief Scientific Officer | Grant/award (A): 128,000 (derivative) @ $0 · Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2022-02-28 | 4 | TZIANABOS ARTHUR — President & CEO, Director | Grant/award (A): 350,000 (derivative) @ $0 · Grant/award (A): 58,000 (derivative) @ $0 | EDGAR |
| 2022-02-28 | 4 | Smith W Bradford — CFO & Treasurer | Grant/award (A): 126,000 (derivative) @ $0 · Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2022-01-12 | 4 | Seymour Albert — Chief Scientific Officer | Option exercise (M): 4,290 · Sale (S): 1,661 @ $3.78 · Option exercise (M): 4,290 (derivative) @ $0 | EDGAR |
| 2022-01-12 | 4 | TZIANABOS ARTHUR — President & CEO, Director | Option exercise (M): 13,860 · Sale (S): 5,354 @ $3.78 · Option exercise (M): 13,860 (derivative) @ $0 | EDGAR |
| 2022-01-12 | 4 | Smith W Bradford — CFO & Treasurer | Option exercise (M): 6,600 · Sale (S): 2,182 @ $3.78 · Option exercise (M): 6,600 (derivative) @ $0 | EDGAR |
Recent 8-K events — Q32 Bio Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-30 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-14 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-15 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-13 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-13 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=FIXX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs